Determination of average crystallite shape by X-ray diffraction and computational methods

Understanding crystallite shape is crucial for pharmaceutical development, but traditional methods struggle with large sample sizes. Prior research has shown that crystallite morphology affects powder behavior, but no reliable large-scale method exists. This gap motivated the development of a new approach combining X-ray diffraction and computational modeling. Existing methods rely on microscopy, which is time-consuming and limited to small samples. The need for a scalable solution remains unmet in the field. Current techniques cannot easily adapt to polydisperse systems or larger batches. The challenge lies in translating diffraction patterns into shape estimates without direct imaging. This paper's contribution is a novel computational method to estimate average crystallite shapes from XRPD data. The approach aims to bridge the gap between structure and morphology in pharmaceutical powders.

The study aimed to create a method for estimating crystallite shape using X-ray powder diffraction data and computational tools. The specific problem is the lack of scalable methods for determining morphology in large pharmaceutical batches. The motivation comes from the need to improve powder processing and formulation. The authors sought to correlate XRPD peak intensities with crystallite shape in oriented samples. They wanted to develop a model that could predict average shape from diffraction patterns. The method needed to be adaptable to larger sample sizes than microscopy allows. The goal was to provide a tool for pharmaceutical development where morphology impacts performance. The study focused on organic crystalline materials used in drug manufacturing.

The researchers combined X-ray powder diffraction with computational modeling to estimate crystallite shape. They used single-crystal structures to build models of crystal faces. Relative peak intensities in XRPD patterns were linked to face orientations in oriented samples. Enhancement factors were calculated for each crystal face in the model. The Bravais-Friedel-Donnay-Harker morphology was modified using these factors. The combined simple-forms morphology was generated from indexed faces. Acetaminophen and ibuprofen were used as test materials with known habits. The predicted shapes were compared to microscopy observations to validate the method.

The predicted shapes matched closely with those observed under microscopy for acetaminophen and ibuprofen. The method successfully estimated crystallite morphology from XRPD data. Enhancement factors were calculated for each crystal face in the model. The Bravais-Friedel-Donnay-Harker morphology was modified using these factors. The combined simple-forms morphology provided a quantitative shape estimate. The method worked best for materials with known single-crystal structures. Limitations included the need to index crystal faces and the impact of polydispersity. The method proved to be the only viable approach for large sample sizes.

The study proposed a method to estimate crystallite shape using XRPD and computational modeling. The predicted shapes closely resembled those observed with microscopy. The method relies on correlating peak intensities with crystal face orientations. Enhancement factors were used to modify the Bravais-Friedel-Donnay-Harker morphology. The approach is limited by the need to index crystal faces and crystallite size. Polydisperse systems may affect the accuracy of the calculations. The method is currently the only viable option for large sample sizes. The authors suggest it could help overcome bottlenecks in pharmaceutical powder analysis.